back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2022-09-29 10:33 Tx date 2022-09-28 |
$PHC
Pathway Health Corp. (formerly Colson Capital Corp.) |
Yoon, Kae-Won
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$29,005
+580,118 vol $0.05 each |
1,580,118 | |
| Filed 2021-11-29 13:59 Tx date 2021-11-26 |
$PHC
Pathway Health Corp. (formerly Colson Capital Corp.) |
Yoon, Kae-Won
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,875
+25,000 vol $0.195 each |
75,000 | |
| Filed 2021-06-15 16:33 Tx date 2021-06-09 |
$PHC
Pathway Health Corp. (formerly Colson Capital Corp.) |
Yoon, Kae-Won
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$500,000
+1,000,000 vol $0.50 each |
1,000,000 | |
| Filed 2021-06-15 16:32 Tx date 2021-05-31 |
$PHC
Pathway Health Corp. (formerly Colson Capital Corp.) |
Yoon, Kae-Won
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-08 13:30 Tx date 2021-05-31 |
$PHC
Pathway Health Corp. (formerly Colson Capital Corp.) |
Yoon, Kae-Won
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
25,000 | ||
| Filed 2021-06-08 13:29 Tx date 2021-05-31 |
$PHC
Pathway Health Corp. (formerly Colson Capital Corp.) |
Yoon, Kae-Won
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
50,000 | ||
| Filed 2018-08-15 Tx date 2018-08-15 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$15,840
+72,000 vol $0.22 each |
559,900 | |
| Filed 2018-08-15 Tx date 2018-08-15 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,880
+28,000 vol $0.21 each |
487,900 | |
| Filed 2018-03-26 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,287
+26,500 vol $0.275 each |
26,500 | |
| Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$81.00
+300 vol $0.27 each |
26,800 | |
| Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$20,412
+72,900 vol $0.28 each |
459,900 | |
| Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+316,598 vol |
1,316,598 | |
| Filed 2017-12-21 Tx date 2017-12-18 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RESP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$14,910
+49,700 vol $0.30 each |
49,700 | |
| Filed 2017-12-21 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RESP (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-11-21 Tx date 2017-11-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,440
+32,000 vol $0.17 each |
191,000 | |
| Filed 2017-11-21 Tx date 2017-11-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$33,320
+196,000 vol $0.17 each |
387,000 | |
| Filed 2017-11-17 Tx date 2017-11-14 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,812
+12,500 vol $0.145 each |
149,500 | |
| Filed 2017-11-17 Tx date 2017-11-13 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,680
+62,000 vol $0.14 each |
137,000 | |
| Filed 2017-11-17 Tx date 2017-11-15 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,330
+9,500 vol $0.14 each |
159,000 | |
| Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+500,000 vol $0.12 each |
1,000,000 | |
| Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,750
+75,000 vol $0.13 each |
75,000 | |
| Filed 2017-11-13 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-06-06 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
500,000 | |
| Filed 2017-06-06 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|